09:14 AM EDT, 08/18/2025 (MT Newswires) -- Aspire Biopharma ( ASBP ) said Monday that its sublingual aspirin product showed "positive" results in a recently concluded trial to treat suspected acute myocardial infarction, commonly known as a heart attack.

Aspire said that, relative to standard chewed aspirin tablets, the sublingual aspirin showed "dramatically higher and more rapid therapeutic impact," including faster onset of action, rapid absorption through blood vessels directly, and ease of use in the case of emergencies.

The company said its sublingual aspirin was well-tolerated by patients and that adverse events were not observed.

Aspire said it plans to review the trial results with the US Food and Drug Administration in the hopes of obtaining accelerated approval for its product.

Shares of Aspire were up more than 100% in recent Monday premarket activity.